Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Completed Phase 2 Trials for Leucovorin (DB00650)
Also known as: Resectable Pancreatic Ductal Adenocarcinoma
| Indication | Status | Phase |
|---|---|---|
| DBCOND0115304 (Resectable Pancreatic Ductal Adenocarcinoma (PDAC)) | Completed | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT02178709 | A Phase II Study of Neoadjuvant FOLFIRINOX | Treatment |